Other languages Perseus Proteomics Inc.

Equities

4882

JP3836800007

Market Closed - Japan Exchange Other stock markets 11:30:00 16/05/2024 am IST			5-day change	1st Jan Change
311 ^JPY	-6.04%		-4.31%	-49.68%

10/05	Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera	CI
07/03	Perseus Proteomics Inc. announced that it has received ¥1.566 million in funding from Barclays Bank PLC (Tokyo Branch)	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera	10/05
Perseus Proteomics Inc. Reports Earnings Results for the Nine Months Ended December 31, 2023	14/02
Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera	02/02
Perseus Proteomics Inc. Reports Earnings Results for the Half Year Ended September 30, 2023	13/11
Perseus Proteomics Inc. Announces Completion of Patients Enrollment in Phase I Clinical Trial for Polycythemia Vera (PV)	20/23/20
Perseus Proteomics Inc. Announces Sales Launch of New Antibodies/Reagents	11/23/11
Perseus Proteomics, Inc. Announces Provision of Antibody Research Support Service Through Single Cell Cloning Technology	27/23/27
Perseus Proteomics Inc. Announces on Dosing of the First Patient in Phase I/II Clinical Trial for Aggressive NK-Cell Leukemia	22/23/22
Perseus Proteomics, Inc. Announces MOU Agreement on Joint Research on Super-Neutralizing Antibody with University of Toyama and Toyama Prefecture	29/23/29
Perseus Proteomics Inc. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2024	14/23/14
Perseus Proteomics Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	14/23/14
Perseus Proteomics Inc. Announces the Interim Report of Phase I Clinical Trial of PPMX-T003	29/23/29
Perseus Proteomics Inc. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2024	12/23/12
Perseus Proteomics Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	12/23/12
Perseus Proteomics Inc. Updates Financial Forecast for the Year 2022	25/23/25
Perseus Proteomics Inc. Announces That PMDA Has Finished Investigation of the Clinical Trial Notification of the Phase I/II Investigator-Led Clinical Trial	27/23/27
Perseus Proteomics Inc. Submits the Clinical Trial Notification of the Phase I/II Investigator-Led Clinical Trial Among Aggressive Nk-Cell Leukemia Patients Using In-Development Anti-Transferrin Receptor Antibody PPMX-T003 as A Therapeutic to the PMDA by Hiroshima University Hospital	15/23/15
Perseus Proteomics Inc. Reports Earnings Results for the Nine Months Ended December 31, 2022	13/23/13
Perseus Proteomics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	13/23/13
Perseus Proteomics Inc. Announces Extension of Phase I Clinical Trial of PPMX-T003 among Polycythemia Vera Patients	07/23/07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Perseus Proteomics Inc.

Equities

4882

JP3836800007

Other languages

Filters